Bexarotene (Targretin s , Ligand Pharmaceuticals Inc.) is a synthetic high-affinity RXR receptor agonist with limited affinity for RAR receptors. Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers. However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer models. In this study, we have investigated the ability of bexarotene to inhibit lung tumor progression in the mutant A/J mouse models with genetic alterations in p53 or K-ras, two of the most commonly altered genes in human lung tumorigenesis. Mice were administered vinyl carbamate (VC), a carcinogen, by a single intraperitoneal injection (i.p.) at 6 weeks of age. Bexarotene was given by gavage starting at 16 weeks after VC and was continued for 12 weeks. Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice. Bexarotene inhibited both tumor multiplicity and tumor volume in mice of all three genotypes. Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by B50% in both p53 wt/wt K-ras ko/wt and p53 wt/wt K-ras wt/wt mice. Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression.
Introduction
Lung cancer is the most common cause of cancer mortality in men and women in the US (Sekido et al., 2003) . The majority of lung cancer is attributable to the use of tobacco products, tobacco smoking, and, in some cases, other environmental risk factors (Garfinkel and Silverberg, 1991; Sekido et al., 2003) . Although the relative risk of developing lung cancer declines in smokers who quit, former smokers remain at risk for the disease (Garfinkel and Silverberg, 1991) . Thus, both former and current smokers are likely to be responsive to improved disease management, early diagnosis, and chemopreventive strategies.
The most frequently used mouse model of pulmonary tumorigenesis is the A/J mouse, which is highly susceptible to the development of both spontaneously occurring and chemically induced lung tumors (Stoner, 1991; Malkinson, 1992) . More than 50 chemicals have been tested for chemopreventive efficacy in the A/J mouse (Stoner, 1991; Malkinson, 1992; Herzog et al., 1997) . Generally, there are three protocols (complete, postinitiation, and tumor progression) commonly used for testing the effect of chemopreventive agents on chemically induced lung tumorigenesis in A/J mice, based on the mechanism of action of the agents and the stages of tumor progression. As shown in Figure 1a , the complete chemoprevention protocol involves intervention beginning 1-2 weeks before carcinogenic initiation and continuously thereafter. This model is frequently used to examine agents that either block carcinogen initiation and/or suppress tumor growth. However, only limited lung tumor progression (from adenomas to adenocarcinomas) occurs when animals are terminated at 20-24 weeks post-carcinogen initiation. The postinitiation chemoprevention protocol gives the agent 2-3 weeks post-carcinogen initiation and continues until 20-24 weeks for determination of the tumor suppressing effects independent of tumor initiation. The tumor progression chemoprevention protocol is designed to determine the effects of preventive agents on progression from adenomas to carcinomas by intervening at 12-20 weeks post-carcinogen initiation and continuing the study to approximately 30 weeks post-carcinogen initiation. The latter is perhaps the most relevant protocol because the transition from adenomas to carcinomas is the most frequent target for clinical chemoprevention trials in humans.
Although some molecular changes found in mouse lung tumors have similarities to those seen in humans, some changes found in human lung cancer are not observed in the more benign mouse lesions. For example, there is a very low incidence of p53 inactivation in A/J mouse lung tumors (o5%), while p53 alterations are found in most human lung tumors (You and Bergman, 1998; Zhang et al., 2000; Hofsteth et al., 2004) . While mutations in K-ras are commonly observed in lung tumors from A/J mice, loss of the wt allele appears to be uncommon (Zhang et al., 2001) . This is in contrast to many human non-small-cell lung cancers or lung adenocarcinomas from B6C3F1 mice where loss of one copy of the K-ras allele, often associated with mutation of the other allele, is relatively common (Zhang et al., 2001; Li et al., 2003) . Therefore, we have developed models that carry a p53 val135 dominantnegative mutation or a K-ras deletion on the A/J mouse background. The mutants carrying p53 or K-ras defects produce lung tumors with >20% adenocarcinomas at 4-6 months when treated with urethane, a lung carcinogen (Zhang et al., 2001; Wang et al., 2003) , which allows one to determine if potential chemopreventive/chemotherapeutic agents inhibit the growth and progression of an established preneoplastic lesion to a malignant tumor and/or cause the regression of these lesions. This is important since individuals involved in the testing of potential chemopreventive agents in cancer-free current or former smokers will have established preneoplastic lesions (Tong et al., 1996) . Thus, a successful chemopreventive agent must be able to inhibit both the formation of new lesions and the progression of existing lesions to tumors.
Retinoids are vitamin A analogues, which function as regulators of cell growth, differentiation, and apoptosis (Mangelsdorf et al., 1994; Nason-Burchenal and Dmitrovsky, 1999 ). These agents have been shown to primarily work through specific nuclear receptors. The first groups of receptors were designated retinoic acid receptors (Mangelsdorf et al., 1994; Nason-Burchenal and Dmitrovsky, 1999) , while a second group of retinoid-related receptors designated RXR (retinoid X receptors) have been identified more recently (Heyman et al., 1992) . Both groups of receptors have been shown to regulate gene expression (Ahuja et al., 2003) . The natural ligand for the RXR receptors is 9-cis retinoic acid (9cRA), which interacts with high affinity both to the RAR and RXR receptors. However, 9cRA-and RAR-selective retinoids were found to have significant side effects that made their use as cancer chemopreventive agents problematic. Based on the isolation of these RXR receptors, a variety of synthetic agonists have been produced. Recent preclinical reports showed that the RXR-selective retinoids are highly effective at inhibiting the development of ER-positive or ER-negative mammary cancer (Gottardis et al., 1996; Wu et al., 2002) and they appear to be less toxic than the RAR-selective retinoids. Boehm et al. (1994) developed the synthetic RXR agonist 4- [1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid and it was named bexarotene (Targretin s , Ligand Pharmaceuticals Inc.).
Bexarotene is an RXR-selective agonist that minimally binds RAR receptors (Boehm et al., 1994) , and it is the first synthetic RXR-selective agonist to enter clinical trials for cancer therapy indications (Miller et al., 1997) . The RXR receptors form heterodimers with a wide variety of nuclear receptors, including the peroxisome proliferator-activated receptors (PPARa, PPARg, and PPARd), the farnesoid X receptor (FXR), the constitutive androstane receptor (CAR) receptor, the RAR receptors (a, b, g), the vitamin D receptors, and the liver X receptors (LXRa and LXRb) (Mangelsdorf and Evans, 1995 Based on mechanism of action of the agents and the stages of tumor progression, three protocols are frequently used for testing the efficacies of chemopreventive agents using A/J mice. In complete chemoprevention protocol, testing agent(s) is administrated 2 weeks before initiation of the carcinogen and continued till the end of experiment, which is usually at 20-26 weeks. In the postinitiation chemoprevention protocol, testing agent(s) is given 2-3 weeks post-carcinogen initiation and continues to 20-24 weeks. In the tumor progression protocol, the testing agent(s) is given at 12-20 weeks post-carcinogen initiation and continues to 30-40 weeks post-carcinogen initiation. Arrow, carcinogen initiation and this time is regarded as week 0. Arrow head, starting time of intervention which will last until the end of experiment. (b) Experimental design of the present study. Experimental design for chemoprevention by bexarotene on VC-induced lung tumors in A/J mice carrying a dominantnegative p53 or heterozygous deletion of K-ras is illustrated. Mice received single i.p. injection of VC at week 0 (indicated by arrow). At 16 weeks after the VC treatment (arrow head), mice were given either vehicle control or testing agent for 12 weeks. The experiment was completed 28 weeks after VC treatment and pathology were scored. The horizontal lines indicated the time by weeks that mice were treated with VC-control (solid line) and with VC þ Bexarotene (dotted line), respectively.
Prevention of lung cancer progression by bexarotene Y Wang et al Saini et al., 2004) . The resulting heterodimers serve as transcription activators of a wide variety of genes. These receptors play major roles in glucose (PPARg), triglycerides (PPARa), cholesterol (PPARd, LXR), bile acid (FXR), and xenobiotic (CAR receptor) metabolism. Bexarotene has been shown to have antiproliferative activity in preclinical in vitro and in vivo models, including human tumor xenografts of head and neck carcinomas. Bexarotene can reduce the volume of skin papillomas in the 7,12-dimethylbenz(a)anthracene-induced SENCAR mouse two-stage skin papilloma model. In the N-nitroso-N-methylurea-induced ERpositive rat mammary tumor model, bexarotene showed a 90% reduction in tumor burden and tumor incidence compared with control rats (Bischoff et al., 1998) . Similarly, bexarotene has proven highly effective in preventing ER negative mammary tumors in transgenic mice (Wu et al., 2002) . Finally, bexarotene treatment decreases proliferation and increases apoptosis in both ER-positive and ER-negative mammary tumors (Bischoff et al., 1999; Wu et al., 2002; p 26. Lubet et al., 2005) . In these animal models, bexarotene was well tolerated without the classic signs of traditional retinoid toxicities. The animal models used in this study were A/J mice, p53 transgenic mice on A/J background, and K-ras heterozygous knockout mice on A/J background. Vinyl carbamate (VC) was given to mice by a single intraperitoneal (i.p.) injection at 6 weeks of age. Bexarotene was given by gavage starting at 16 weeks after VC and was continued for an additional 12 weeks. Bexarotene exerted significant efficacy on lung tumor progression and growth in these mouse models regardless of the genotypes. UL53-3 mice were originally generated on FVB mouse background with a 135val p53 mutation. The N10 (A/J Â UL53-3) mice are 10 times backcrossed UL53-3 mice (p53 transgenic mice) onto the A/J strain. All the animals were genotyped for p53 and K-ras by PCR as previously described (Zhang et al., 2001; Wang et al., 2003) . Although the K-ras knockout and p53 transgenic were from a different genetic background, that is, C57BL/6 or FVB/J, they have been backcrossed to A/J through selected breeding to ensure the appropriateness of statistical comparison. In backcrossing these knockout or transgenic mice onto the A/J background, we used a selected breeding strategy that is also called 'speed congenics'. We have genotyped the progeny of each generation of backcrossing using B50 genetic markers across the whole genome to select the progeny with the least donor DNA for additional backcrossing. Generally, this process would lead to the creation of a congenic strain with less than 0.5% contaminating donor genome unlinked to the locus of the knockout or transgene in only five generations of backcrosses. For p53 transgenic mice, the animals were paired to set up breeding colonies for production of (A/J Â UL53-3)F 1 mice and they were used to cross breed with A/J mice for 10 generations. Similarly, the N7(A/J Â K-ras) mice are generated by backcrossing K-ras ko/wt mice to the A/J strain seven times. Thus, our lines of knockout or transgenic mice (N10 or 7) should have B100% of the A/J genetic backgrounds after 10 or seven generations of backcrossing using selected breeding strategy, which would make the direct comparison between different groups of mice appropriate in this study.
Materials and methods

Reagents and mice
Bioassay
As illustrated in Figure 1b and Table 1 ) were divided into control and treatment groups. Mice were given a single i.p. injection of 60 mg/kg body weight of VC at 6 weeks of age. This time is counted as week 0. At 16 weeks after the VC treatment, mice were given Bexarotene (100 mg/kg body weight, by gavage with 18 gage of gavageneedle, 0.1 ml per mouse per day, 5 times a week). We used the dose of 100 mg/kg bexarotene in this study because bexarotene exhibited a significant efficacy against breast tumorigenesis and no toxicity in previous studies at this dose (Bischoff et al., 1998 (Bischoff et al., , 1999 Lubet et al., 2005) . The suspension of bexarotene was prepared in corn oil (MAZOLA, Supermarket). Body weights and clinical evidence of toxicity were monitored weekly throughout the experiment. The experiment was Approximately equal numbers of males and females were used, with no significant difference in tumor multiplicity between the sexes. At 6 weeks of age, mice in all groups were given single i.p. injection vinyl carbamate (VC) (60 mg/kg, i.p.). Mice in groups 2, 4, and 6 received gastric gavage of bexarotene 100 mg/kg in corn oil (0.1 ml/mouse). Mice in groups 1, 3, and 5 received gastric gavage of the vehicle (0.1 ml corn oil/mouse). The numbers in this formalin (10% v/v buffered formalin) overnight, followed by 70% ethanol. The lungs were step sectioned and the slides were stained with H&E for histopathological evaluation. Lung tumor number (N), volume (V), and total tumor load (N Â V per mouse) were also scored. The tumor volumes were determined by measuring the diameter of each tumor, which is generally in a round shape. The radius (r ¼ diameter/2) was determined, and the total tumor volume was calculated by volume ¼ (4/3)pr 3 .
Statistical analysis
We hypothesized that VC-induced lung tumors are more likely to occur in the carcinogen control group than in the treatment group in three mouse models used. ) and treatment with bexarotene. We applied squareroot transformation of tumor numbers since the original data did not follow normal distribution. The transformed data were of normal distribution (data not shown). Accordingly, Student's t-test was used to test the differences between the treatment for each genotype, and the differences between wildtype and the other two genotypes.
Microarray analysis using affymetrix GeneChip s Total RNAs were isolated from three normal lungs, four lung tumors, and three bexarotene-treated lung tumors of p53 val135/wt mice by Trizol (Invitrogen, Carlsbad, CA, USA) and purified with RNeasy Mini Kit and RNase-free DNase Set (QIAGEN, Valencia, CA, USA) according to the manufacturer's protocols. cDNA was synthesized using Superscript cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) and purified using phase-lock gel (Fisher Cat ID E0032005101). Biotin-labeled cRNA was then transcribed from cDNA using a BioArray HighYield RNA Transcript Labeling Kit (ENZO Biochem, New York, NY, USA). The labeled cRNA was applied to the Affymetrix Mu74Av2 GeneChips (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's recommendations. Array normalization and gene expression estimates were obtained using Affymetrix Microarray Suite 5.0 software (MAS5). Differential expression was determined on the combined basis of statistical testing using t-test and fold changes. A cutoff of Pp0.001 and fold X2 is called positive for differential expression. For the selected genes, expression indices were transformed across samples to an N (0,1) distribution using a standard statistical Z-transform. These values were input to the GeneCluster program and genes were clustered using average linkage and correlation dissimilarity. In order to investigate potential mechanism, we used GenMapp as a visual tool to interpret these modulated genes. We imported our data set, at cutoff of Pp0.05 and fold X1.5, into the GenMAPP 2.0 Beta (UCSF, www.genmapp.org) (Dahlquist et al., 2002) program to evaluate several important pathways, such as apoptosis, cell cycle regulation, signal transduction pathways, and metabolic pathways. Differential gene expression was based on bexarotene treatment versus nontreatment expression changes in VC-induced lung tumors.
Quantitative real-time RT-PCR Seven of the altered genes were selected for confirmation by RT-PCR analysis using SYBR Green Assay (Bio-Rad Laboratories, Hercules, CA, USA) on the ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). The mouse b-actin was used as the reference control for normalization of template equal loading. RNAs from four individual lung tumors of p53 val135/wt were tested with four individual RNAs of normal lungs of same genotype as normal controls. Each sample was run in duplicate for both tested genes and for mouse b-actin. The amplifications were carried out by a hot-start at 951C for 2 min, followed by 40 cycles of 951C for 15 s and 581C for 45 s.
Results
The experimental design is shown in Figure 1b . We observed a significant increase in lung tumor progression in mice with a mutation in the p53 gene (p53 ) when compared with those seen in wt mice (p53 wt/wt K-ras wt/wt ). We use the term 'tumor progression' here to describe the process of tumor development from lung adenoma to lung adenocarcinoma. In this study, detailed histopathological examinations were carried out to determine the degree of lung tumor progression related to the effect of the p53 transgene and K-ras knockout, and the effect of the chemopreventive agents on tumor progression. As shown in Figure 2 , lung adenocarcinomas are composed of cells with varying degrees of differentiation with most cells appearing relatively undifferentiated compared to lung adenomas. Lung adenomas contain cells that are monomorphic and well differentiated supported by a thin layer of fibrovascular stroma. There is a complete loss of normal alveolar architecture, and the nuclear: cytoplasmic ratio is increased in the carcinomas. Nuclear crowding and cytologic atypia are present, and there is heterogeneity of growth patterns. Invasion into adjacent bronchioles or vessels is also observed. However, no metastasis was seen in these mice. As shown in Table 1,  treatment of p53 wt/wt K-ras ko/wt mice with VC induced an average of 4.4 lung adenocarcinomas per mouse (n ¼ 10) versus an average of 1.1 lung adenocarcinomas/mouse (n ¼ 14) in p53 wt/wt K-ras wt/wt mice (P ¼ 0.01). Similarly, p53 val135/wt K-ras wt/wt developed an average of 4.3 lung adenocarcinomas/mouse (n ¼ 8) after treatment with VC versus an average of 1.1 lung adenocarcinomas/mouse (n ¼ 14) in p53 wt/wt K-ras wt/wt mice (Po0.01). These results demonstrate that the mutant p53 or K-ras heterozygous deficiency significantly enhances tumor progression from lung adenomas to lung adenocarcinomas and these two models are suited for determining the efficacy of chemopreventive agents on lung tumor progression.
Using our lung tumor progression models, the chemopreventive efficacy of bexarotene was examined in wt mice (p53 wt/wt K-ras wt/wt ), mice with a mutation in the p53 gene (p53 val135/wt K-ras wt/wt ), and mice with heterozygous deletion of K-ras gene (p53 wt/wt K-ras ko/wt ). We monitored body weights and visible evidence of toxicity weekly throughout the experiment and no significant changes in body weights or any sign of toxicity were observed (data not shown). As seen in val135/wt K-ras wt/wt mice. These results indicate a strong inhibitory effect of bexarotene on the progression from lung adenomas to adenocarcinomas in these mutant mouse models. The effect of bexarotene on tumor progression was in parallel with its ability to inhibit tumor growth.
Next, we conducted microarray studies in an attempt to determine the mechanism(s) of action for bexarotene. Among 45 000 probe set on the chip, 4304 of them altered in VC-induced lung tumors as compared to the normal lung controls. Among them, there are 2366 underexpressed and 1938 overexpressed. Interestingly, 311 underexpressed and 358 overexpressed genes were modulated towards to normal expression level by bexarotene treatment ( Figure 3A ). Differential gene expression was based on bexarotene treatment versus nontreatment expression changes in VC-induced lung tumors. In Table 2 , we listed a selected group of cancerrelated genes, whose expression was altered in lung tumors and were modulated towards to normal level by bexarotene. We imported our data set into the GenMAPP program to evaluate pathways, such as apoptosis, cell cycle regulation, signal transduction, and metabolism. As shown in the cell cycle regulation pathway ( Figure 3B ), Rb1 and Bub3 (a mitotic checkpoint protein) were underexpressed in VC-induced lung tumors and they were modulated toward normal level by bexarotene, while Chek1, Mcm6 (minichromosome maintenance helicase 6), and Hdac6 (histone acetylase 6) were overexpressed in VC-induced lung tumors and they were modulated toward normal level by bexarotene. Finally, seven altered genes were selected for confirmation using real-time RT-PCR analysis including arachidonate 5-lipoxygenase (Alox5), retinoic acid receptor beta (RARb), CDK inhibitor 1B (p27, Cdkn1b), CDK inhibitor 2A (Cdkn2a), Kit oncogene (Kit), estrogen receptor b (ER2), and Pik3 regulatory subunit p85a (Pik3r1). All of them were shown similar changes in both Microarray analysis and RT-PCR ( Figure 3C ).
Discussion
Mouse lung carcinogenesis is a multistage process consisting of initiation, promotion, and progression (Stoner, 1991; Malkinson, 1992; You and Bergman, 1998) . Genotoxic carcinogens induce irreversible genetic alterations, whereas the nongenotoxic tumor promoters stimulate tumor development by favoring the clonal outgrowth of the genetically altered cells. Progression is the process whereby a noninvasive lesion, that is, an adenoma, is converted into an invasive lesion, for example, an adenocarcinoma. Only a few previous studies of chemopreventive agents in lung carcinogenesis have focused on tumor progression since most of those studies terminated the assays at lung adenoma stages and these adenomas have limited histopthologic or genetic alterations when compared to adenocarcinomas This table lists two sets of genes. In the set A, gene expression was downregulated in VC-induced mouse lung tumors and these downregulations were modulated towards to normal level by bexarotene treatment. In the set B, gene expression was upregulated in VC-induced mouse lung tumors and these upregulations were modulated towards to normal level by bexarotene treatment.
Prevention of lung cancer progression by bexarotene Y Wang et al observed in humans (You and Bergman, 1998) . We have recently explored the use of genetically altered mice, with mutations in p53 or an Ink4a/Arf deficiency, which more closely parallel human lung cancer . The objective was to develop models that are closer to human lung cancer and are more likely to progress to malignant tumors. In this study, we have expanded this to a third model which has a knockout of one copy of the K-ras gene (Zhang et al., 2001) . The rationale for this alteration is twofold. First, loss of heterozygosity at the K-ras locus is relatively common in human lung cancers (Li et al., 2003) . Second, a decrease in dosage of the K-ras wild-type allele has been shown to promote urethane-induced mouse lung tumorigenesis (Zhang et al., 2001) . Introduction of a dominantnegative p53 mutant (Ala 135 Val) into the germ line or having a heterozygous deletion of the K-ras gene was found to significantly enhance lung tumorigenesis. We observed that VC caused a significant increase in the number of lung adenocarcinomas in K-ras ko/wt mice as compared to their wt littermates, indicating that a decrease in the wt K-ras gene dosage does significantly enhance VC-induced lung tumor progression in K-ras ko/wt mice, at least in the 7-month bioassay. Similarly, VC treatment also resulted in a significant increase in the number of lung adenocarcinomas in p53 val135/wt mice and in K-ras ko/wt mice versus wild-type mice. Thus, mutant p53 or K-ras heterozygous deficiencies are useful mouse models for the study of lung tumor progression from adenomas to adenocarcinomas. In addition, these models should be applicable for studies targeting tumor progression in screening for preventive and/or therapeutic agents relevant to lung cancer.
In the present study, bexarotene significantly prevented lung adenocarcinoma development in both wt mice and mice with defect in p53. In bexarotene-treated groups, the number of lung adenocarcinomas was significantly reduced in wild-type and p53 val135/wt as well as, to a lesser degree (not statistically significant), in Kras ko/wt mice when compared to those of control mice. Bexarotene clearly retards the appearance of lung adenocarcinomas. Thus, it inhibits the progression of adenomas to adenocarcinomas when bexarotene is given in a therapeutic setting from weeks 16 through 28 post initiation. This is associated with more than 40% decrease in tumor volume in bexarotene-treated mice with either a p53 mutation or K-ras heterozygous knockout. Consistent with our preclinical results in mouse lung cancer models, Khuri et al. (2001) combined bexarotene with cisplatin and vinorelbine in the treatment of patients with non-small-cell lung cancers and they showed a 25% response rate with better-thanexpected survival rates in a phase I/II trial (Khuri et al., 2001) . Furthermore, bexarotene has shown efficacy in other preclinical tumor models (Bischoff et al., 1999; Wu et al., 2002; Lubet et al., 2005) . For example, bexarotene inhibited growth and caused complete regression of 72% of NMU-induced rat mammary carcinomas and also caused complete regression of tumors that previously failed to respond to tamoxifen (Bischoff et al., 1998) . Interestingly, several reports found that there were few or no toxic side effects associated with bexarotene's efficacy in tumor models although bexarotene does increase triglyceride levels in both humans and rats (Bischoff et al., 1998 (Bischoff et al., , 1999 Konopleva and Andreeff, 2002; Lee and Cohen, 2002; Lubet et al., 2005) .
The mechanism for the observed chemopreventive effective of bexarotene is not clear at present. RXRs have been known to regulate gene expression in a ligand-dependent (forming permissive heterodimeric complexes) or a ligand-independent (forming nonpermissive heterodimeric complexes) manner. Since RXR receptors form heterodimers with such a wide variety of nuclear receptors means that RXR agonists will affect expression of genes in a wide variety of tissues. For example, bexarotene decreases IGF-1 expression in serum (Mangelsdorf et al., 1994) , presumably by affecting liver production of IGF-1. IGF is one potential contributor to the efficacy of bexarotene since low IGF-1 levels have been proposed to decrease tumorigenesis. However, RXR interacts with numerous nuclear receptors in the target tissue which have been proposed to affect tumorigenesis, including: (1) A PPARg/RXR heterodimer is involved in tumour growth inhibition and has been shown to bind directly to nuclear estrogen response elements (ERE) independently of estrogen receptor (ER) activity. Interactions of PPARg with RARa, protein kinase R (PKR), PTEN, and mitogenactivated protein kinase (MAPK) have been described (Nason-Burchenal and Dmitrovsky, 1999) . (2) RXRa is required for the apoptosis-inducing effects of IGFBP-3. IGFBP-3 and RXR ligands are additive in inducing apoptosis in cancer cells (Ahuja et al., 2003) . (3) Bexarotene inhibited the growth and caused complete regression in 72% of NMU-induced rat mammary carcinomas (Gottardis et al., 1996) . Owing to the very wide variety of gene expression changes associated with RXR agonists, it may be difficult to determine which gene changes are most important. There are a few generalized approaches. One would look at agonists for specific nuclear receptors and see whether they give a similar result. The second would be to look for nonspecific changes, for example, antiproliferative or apoptotic effects, and then determine whether microarray data gives further specific insights. Both approaches will be considered in our future studies. In the present study, we found that at least 669 genes can be modulated by bexarotene treatment including 311 underexpressed and 358 overexpressed genes. The GenMAPP analysis indicates several genes affecting the cell cycle regulation were modulated by bexarotene. For example, Rb1 and Bub3 were upregulated and Chek1, Mcm6, and Hdac6 were downregulated by bexarotene. In addition, members of the CDK inhibitors (Cdkn1b and Cdkn2a) and retinoic acid receptors (RARb) as well as estrogen receptors (ERb) were modulated by bexarotene treatment, suggesting the involvement of cell cycle regulators and various receptors in the chemopreventive efficacy of bexarotene against lung carcinogenesis. Investigations into the exact molecular mechanism(s) of action of bexarotene are being pursued.
To our knowledge, this is the first report on the potent effect of bexarotene on lung tumor progression in transgenic mouse models. We have shown that bexarotene decreased tumor progression and growth in genetically modified models of lung cancer. The late intervention, 16-28 weeks post VC, which we employed appears similar to potential phase II clinical trials where current or former smokers with pre-existing lesions would be examined. We believe that individuals with precancerous lesions of the lung with a high risk of developing lung adenocarcinomas could benefit from effective agent like bexarotene to inhibit their progression on the basis of results from preclinical studies and human clinical trials (Gottardis et al., 1996; Miller et al., 1997; Bischoff et al., 1999; Khuri et al., 2001; Zhang et al., 2004; Lubet et al., 2005) . Bexarotene exhibited a 25% response rate with a better survival rates when combined with cisplatin and vinorelbine in the treatment of patients with non-small-cell lung cancers in a phase I/ II trial (Khuri et al., 2001) . In other Phase I clinical trials for the treatment of cancer, bexarotene was found to suppress the growth of cutaneous lymphoma and has now been approved for the treatment of cutaneous T-cell lymphoma (Miller et al., 1997) . In these clinical studies, bexarotene was generally well tolerated with hypertriglyceridemia as the most common side effect (Miller et al., 1997; Khuri et al., 2001) . Although the incidence of hypertriglyceridemia was similar to other studies in patients with cutaneous lymphoma and lung cancer, hypertriglyceridemia is generally easily managed with fenofibrate therapy (Khuri et al., 2001) . Hypothyroidism was noted in patients treated with bexarotene at higher doses (1300 mg/m 2 /day) (Sherman et al., 1999) . Since p53 and K-ras appear to be the most commonly mutated genes in human non-small-cell lung carcinomas, agents that are effective in tumors with these mutations are particularly appealing. Thus, bexarotene may have the potential for use in subjects at high risk of lung cancer.
